Evaluation of Pharmacodynamic Interaction Between Berberine and Antibacterial Drug (Azithromycin) in Albino Wistar Rats

Q3 Pharmacology, Toxicology and Pharmaceutics

Current Trends in Biotechnology and Pharmacy Pub Date : 2021-08-18 DOI:10.5530/CTBP.2021.3.28

Suchita Gupta, Reena Gupta, J. Gupta

{"title":"Evaluation of Pharmacodynamic Interaction Between Berberine and Antibacterial Drug (Azithromycin) in Albino Wistar Rats","authors":"Suchita Gupta, Reena Gupta, J. Gupta","doi":"10.5530/CTBP.2021.3.28","DOIUrl":null,"url":null,"abstract":"Background: Evaluation of pharmacodynamic interaction between Berberine and antibacterial drug (Azithromycin) in Wistar rats. \nMethod: The study aims to evaluate the antimicrobial and antitubercular activities of a combination of berberine and azithromycin against microorganisms (E. coli, S. aureus) and Mycobacterium tuberculosis by using Alamar Blue Assay respectively. The compatibility and hepatoprotective activities of Berberine were also carried out against the azithromycin-induced hepatotoxicity rat model. \nResult: The combination of berberine and azithromycin does not show any compatibility with a single-drug investigated by the Rf value, and synergistic effect against S. aureus and E. coli represented a significant zone of inhibition. Azithromycin showed in-vitro antitubercular activity at all concentrations, and berberine at 6.25μg/ml. Berberine and azithromycin co-administered for 28 days result in increased body weight, albumin level, total protein, and decreased serum transaminase, alkaline phosphatases, and total bilirubin significantly. \nConclusion: The combination of berberine and azithromycin does not show physical interaction, results in no alteration in the drug absorption, and showed antibacterial activity. Phytoconstituents showed antitubercular activity at different concentrations. The hepatoprotective action of berberine was proven by the evaluation of biomarkers of liver and body weight. Histopathological reports of the liver revealed that herbal mixture improves hepatocellular vacuolation and infiltration of inflammatory cells. Finally, based on in-vivo studies concluded that combination showed increased hepatoprotective activity in comparison to individual herbal drug.","PeriodicalId":10980,"journal":{"name":"Current Trends in Biotechnology and Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Trends in Biotechnology and Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5530/CTBP.2021.3.28","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 1

Abstract

Background: Evaluation of pharmacodynamic interaction between Berberine and antibacterial drug (Azithromycin) in Wistar rats. Method: The study aims to evaluate the antimicrobial and antitubercular activities of a combination of berberine and azithromycin against microorganisms (E. coli, S. aureus) and Mycobacterium tuberculosis by using Alamar Blue Assay respectively. The compatibility and hepatoprotective activities of Berberine were also carried out against the azithromycin-induced hepatotoxicity rat model. Result: The combination of berberine and azithromycin does not show any compatibility with a single-drug investigated by the Rf value, and synergistic effect against S. aureus and E. coli represented a significant zone of inhibition. Azithromycin showed in-vitro antitubercular activity at all concentrations, and berberine at 6.25μg/ml. Berberine and azithromycin co-administered for 28 days result in increased body weight, albumin level, total protein, and decreased serum transaminase, alkaline phosphatases, and total bilirubin significantly. Conclusion: The combination of berberine and azithromycin does not show physical interaction, results in no alteration in the drug absorption, and showed antibacterial activity. Phytoconstituents showed antitubercular activity at different concentrations. The hepatoprotective action of berberine was proven by the evaluation of biomarkers of liver and body weight. Histopathological reports of the liver revealed that herbal mixture improves hepatocellular vacuolation and infiltration of inflammatory cells. Finally, based on in-vivo studies concluded that combination showed increased hepatoprotective activity in comparison to individual herbal drug.

查看原文本刊更多论文

小檗碱与抗菌药物阿奇霉素在白化Wistar大鼠体内相互作用的药效学评价

背景:评价小檗碱与抗菌药物阿奇霉素在Wistar大鼠体内的药效学相互作用。方法:采用Alamar Blue法分别评价小檗碱与阿奇霉素联合用药对大肠杆菌、金黄色葡萄球菌和结核分枝杆菌的抑菌和抗结核活性。在阿奇霉素肝毒性大鼠模型下，对小檗碱的相容性和肝保护活性进行了研究。结果:小檗碱与阿奇霉素联用与单药的Rf值不存在配伍性，对金黄色葡萄球菌和大肠杆菌具有明显的协同抑制作用。阿奇霉素在所有浓度下均有体外抗结核活性，小檗碱在6.25μg/ml时均有体外抗结核活性。小檗碱和阿奇霉素联合用药28天导致体重、白蛋白水平、总蛋白水平增加，血清转氨酶、碱性磷酸酶和总胆红素显著降低。结论:小檗碱与阿奇霉素合用不发生物理相互作用，不改变药物吸收，具有抗菌活性。不同浓度的植物成分均表现出抗结核活性。小檗碱的肝保护作用通过肝脏和体重生物标志物的评价得到证实。肝脏的组织病理学报告显示，草药混合物改善肝细胞空泡化和炎症细胞的浸润。最后，基于体内研究得出结论，与单个草药相比，联合用药显示出更高的肝保护活性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Trends in Biotechnology and Pharmacy Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science

CiteScore

0.70

自引率

0.00%

发文量

期刊介绍： The Association of Biotechnology and Pharmacy (ABAP) will be useful to form a forum for scientists so that they can bring together to discuss and find scientific solutions to the problems of society. The annual meetings will help the members to share their knowledge and publish their research knowledge particularly by members and fellows of the Association and special care will be taken to provide an opportunity for young scientists. Besides this the association is planned to organize symposia, seminars and workshops on current developments of Biotechnology and Pharmacy particularly on the subject of current scientific interest, and the proceedings of which will be published regularly. And in view of the vast development of science and to disseminate the problems in publication of research work, an international journal of Current Trends in Biotechnology and Pharmacy has been started by ABAP.